COVAXIN® Production Volumes Ramped Up By Bharat Biotech, To An Additional 200 Million

Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases, announced today, the quick ramp up of additional manufacturing capacities for COVAXIN®, India’s 1st Indigenous Covid 19 Vaccine at CHIRON BEHRING Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech.

The company plans to produce 200 million doses of COVAXIN® per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankleshwar to commence from Q4 2021.

Bharat Biotech had already deployed multiple Production lines at its Hyderabad & Bengaluru campuses, adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN®. This effectively takes the volumes upto ~ 1 Billion doses per Annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.

Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar, Gujarat is a 100% subsidiary of Bharat Biotech International Limited. Chiron Behring Vaccines was formed as a result of the purchase of the vaccines business of Hoechst AG by Chiron Corporation USA. It is one of the largest manufacturers of
high-quality rabies vaccines in the world. Chiron Behring Vaccines is a WHO Pre-qualified manufacturer of rabies vaccines, eligible for supplies to UN agencies and has product registrations in more than 20 countries. Acquiring of Chiron Behring Vaccines Pvt Ltd has established Bharat Biotech as a global leader in rabies vaccines manufacturer.